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Purpose: Alterations of the central serotonergic system have been implicated in the 
pathophysiology of dystonia. In this molecular imaging study, we assessed whether 
altered presynaptic serotonin transporter (SERT) binding contributes to the pathophysi-
ology of cervical dystonia (CD), concerning both motor and non-motor symptoms (NMS).
Methods: We assessed the non-displaceable binding potential (BPND) using the selective 
SERT tracer [11C]DASB and positron emission tomography (PET) in 14 CD patients and 
12 age- and gender-matched controls. Severity of motor symptoms was scored using 
the Toronto Western Spasmodic Torticollis Rating Scale and Clinical Global Impression 
jerks/tremor scale. NMS for depressive symptoms, anxiety, fatigue, and sleep distur-
bances were assessed with quantitative rating scales. The relationship between SERT 
binding and clinical patient characteristics was analyzed with the Spearman’s rho test 
and multiple regression.
results: When comparing the CD patients with controls, no significant differences in 
BPND were found. Higher BPND in the dorsal raphe nucleus was statistically significantly 
correlated (p < 0.001) with motor symptom severity (rs = 0.65), pain (rs = 0.73), and 
sleep disturbances (rs = 0.73), with motor symptom severity being the most important 
predictor of SERT binding. Furthermore, fatigue was negatively associated with the BPND 
in the medial raphe nucleus (rs = −0.61, p = 0.045), and sleep disorders were positively 
associated with the BPND in the caudate nucleus (rs = 0.58, p = 0.03) and the hippocam-
pus (rs = 0.56, p = 0.02).
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conclusion: Motor symptoms, as well as pain, sleep disturbances, and fatigue in CD 
showed a significant relationship with SERT binding in the raphe nuclei. Moreover, fatigue 
showed a significant relationship with the medial raphe nucleus and sleep disorders 
with the caudate nucleus and hippocampus. These findings suggest that an altered 
serotonergic signaling in different brain areas in CD is related to different motor as well as 
NMS, which will further stimulate research on the role of serotonin in the pathogenesis 
of dystonia.
Keywords: dystonia, serotonin, positron emission tomography, DasB, cervical dystonia
inTrODUcTiOn
Cervical dystonia (CD) is a movement disorder characterized 
by involuntary abnormal muscle contractions of the neck. Non-
motor symptoms (NMS) like depressive symptoms, pain, and 
fatigue are prevalent in up to 95%of CD patients (1).
Although the pathogenesis of CD is largely unknown, altera-
tions of the serotonergic system have been suggested to play 
a major role in both motor symptoms and NMS in dystonia 
[for review, see Ref. (2)]. A dense projection of fibers from 
serotonergic neurons, located within the raphe nuclei in the 
brainstem, arises to important structures of the basal ganglia 
motor control system, such as the striatum and internal globus 
pallidus (GPi). The GPi plays a key role in the network underly-
ing the pathophysiology of dystonia (3, 4), a contribution sup-
ported by the therapeutic effect of GPi deep brain stimulation 
for dystonia (3).
Further evidence that alterations of the serotonergic system 
may play a role in the pathogenesis of dystonia, including CD, 
can be inferred from case reports describing dystonia induced 
by selective serotonin reuptake inhibitors. Also, in children with 
dopa-responsive dystonia as well as in adults with idiopathic 
adult-onset dystonia decreased levels of serotonin metabolites in 
cerebrospinal fluid have been reported (5).
Positron emission tomography (PET) provides a unique 
opportunity to study the serotonin transporter (SERT), an 
important presynaptic marker of serotonergic functioning 
in vivo. The PET radioligand [11C]DASB is a well-validated selec-
tive radiotracer to measure SERT binding in the human brain. 
In Parkinson’s disease, [11C]DASB PET studies have shown that 
aberrations of SERT in different brain areas are related to both 
motor and NMS, including tremor severity (6), dyskinesia (7), 
fatigue (8), and depressive symptoms (9).
In this study, we examined SERT binding in CD patients and 
matched controls using [11C]DASB PET imaging and corrected 
for the SERT gene-linked polymorphism. Based on previous 
findings, we hypothesized that dysfunction of the serotonergic 
system is a shared pathophysiological pathway for motor- and 
NMS in CD patients.
MaTerials anD MeThODs
subjects
This case-control study included 14 patients with a clinically 
diagnosed idiopathic CD and 14 age- and sex-matched controls.
Exclusion criteria included the onset of CD before the age 
of 18 years, and severe tremor and/or jerks preventing accurate 
brain imaging due to movement artifacts. Exclusion criteria for 
all subjects were other relevant neurological comorbidity and 
the current use of serotonergic medication or antidepressants. 
Written informed consent was obtained from all participants in 
accordance with the declaration of Helsinki and the study was 
approved by the local ethics committee of the University Medical 
Center Groningen (2014/034). The study was not registered in a 
public trial registry.
clinical Measures
Motor assessment was performed using a systematic video pro-
tocol. If patients were treated with botulinum toxin (n = 12), the 
clinical assessment was performed within two weeks prior to or 
one week after botulinum toxin treatment in order to obtain the 
least influenced motor score. CD motor symptom severity and 
related pain were scored with the Toronto Western Spasmodic 
Torticollis Rating Scale (TWSTRS) (10); severity of jerks and 
tremor were scored using the Clinical Global Impression Scale: 
CGI-S jerks-tremor (11). Motor function was independently 
scored by two experts (MS and VH) and the average score was 
used in the statistical analysis as there was good inter-observer 
agreement (intraclass correlation coefficients >  0.70, two-way 
mixed, absolute agreement).
Non-motor symptoms, including depressive symptoms, anxi-
ety, fatigue, and sleep disturbances, were assessed using the Beck 
Depression Inventory (BDI), the Beck Anxiety Inventory (BAI), 
the Fatigue Severity Scale (FSS), and the Pittsburgh Sleep Quality 
Index (PSQI) (2).
genetics
The SERT gene-linked polymorphic region (5-HTTLPR), encoded 
by the SLC6A4 gene, is an important regulator of the number 
of expressed SERTs. Three different alleles in this polymorphic 
region have been associated with changes in transcriptional activ-
ity. Functionally, the S and LG allele induce low-transcriptional 
activity, while the LA allele induces high-transcriptional activity 
(12). We classified 5-HTTLPR status as LA/LA genotype or LG/S-
allele carrier; details of the methodology are explained in the 
Supplementary Material.
PeT and Mri Data acquisition
Positron emission tomography imaging was performed either 
with a Biograph 40-mCT or 64-mCT (Siemens Healthcare, 
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USA). Head movement was minimized with a head-restraining 
band. After a low-dose CT for attenuation and scatter correction, 
a dynamic 60-min data acquisition scan (23 frames: 7 s × 10 s, 
2  s ×  30  s, 3  min ×  1  min, 2  min ×  2  min, 2  min ×  3  min, 
5  min ×  5  min, and 2  min ×  10  min) was started simultane-
ously to an intravenous bolus injection of [11C]-3-amino-4-(2-
dimethylaminomethyl-phenylsulfanyl)benzonitrile ([11C]DASB) 
(379  ±  44  MBq). Synthesis of [11C]DASB was performed by 
methylation of N-methyl-2-(2-amino-4-cyanophenylthio)-
benzylamine, and the details have been reported elsewhere (13).
Individual axial 3D T1-weighted gradient-echo images (3T 
Intera, Philips, the Netherlands) of the brain were acquired from 
all participants. MR images were visually examined (AB) and no 
significant structural lesions were detected.
image reconstruction and Preprocessing
The list-mode data from the PET scans were reconstructed using 
the 3D OSEM algorithm (3 iterations and 24 subsets), point 
spread function correction, and time-of-flight, resulting in a 
matrix of 400 × 400 × 111 of isotropic 2-mm voxels, smoothed 
with 2-mm filter at full width at half maximum (FWHM).
Image processing and pharmacokinetic analysis were per-
formed with PMOD v3.7 software (PMOD Technologies Ltd., 
Switzerland). Motion correction was applied to the PET images 
(frames 9–23, using frame 15 as reference) to account for the 
movement of the subject during the scan. Then, the summed 
image (frames 13–23) was used for rigid matching registration 
of the individual PET to the individual MRI. A three-tissue prob-
ability map normalization of the individual MRI into the Montreal 
Neurological Institute (MNI) standard space was calculated and 
subsequently applied to the corresponding PET image (14).
Predefined volumes of interest (VOIs) were transformed back 
into individual space, based on the Hammers atlas (15) and limited 
to the gray-matter tissue of cortical regions (>30% gray-matter 
probability based on individual segmentations). In addition, VOIs 
for the dorsal raphe nucleus (dRN) and the median raphe nucleus 
(mRN) were manually defined based on their MNI coordinates 
(atlas based, i.e., dRNa and mRNa) (16). Moreover, driven by 
local signal intensity, extra definitions of dRN and mRN VOIs 
were delineated by selecting 80% of the voxels with the highest 
uptake within a sphere (diameter of 8 mm for the dRN and 6 mm 
for mRN) manually located in these regions, according to visual 
inspection of the PET image (average of frames 20–23) (subject 
based, i.e., dRNs and mRNs).
After spatial registration of the images, pharmacokinetic mod-
eling was performed to obtain the [11C]DASB non-displaceable 
binding potential (BPND) (17), using the simplified reference 
tissue model 2 (SRTM2) (18) with the cerebellum (excluding 
vermis) as the reference region. BPND values were obtained from 
aligned PET images in the individual space for the VOI-based 
analysis, and in the MNI space for the voxel-based analysis. A 
Gaussian kernel of 6-mm FWHM was applied to the PET image 
before voxel-based pharmacokinetic modeling.
statistical analysis
Statistical analysis was performed using SPSS Statistics 22 (IBM 
SPSS Statistics, USA). Demographic and clinical data and the 
values obtained from the VOI-based modeling were compared 
between groups using the Pearson’s χ2 test/Fisher’s exact test or 
the Mann–Whitney U test. Differences were considered statisti-
cally significant at <5% probability (p < 0.05) of equality. In the 
case of significant differences between groups, we additionally 
performed correction for multiple comparisons. Additionally, 
effect sizes were calculated using the Cohen’s d test, which were 
interpreted as d > 0.1: small effect; d > 0.3: medium effect; and 
d > 0.5: large effect (19).
For statistical comparison of the BPND parametric images, a 
two-sample t-test was performed in SPM12 (Wellcome Trust 
Centre for Neuroimaging, UK) between dystonia patients and 
controls. For interpretation of the results, T-maps data were inter-
rogated at p = 0.005 (uncorrected) and only clusters with p < 0.05 
corrected for family wise error were considered significant.
Correlation analysis between the BPND obtained from the 
VOI-based modeling and clinical characteristics was performed 
using the Spearman’s rho test. With multiple regression analysis, 
we then determined the influence of clinical variables with a 
p-value <0.05 in the univariate analysis on the BPND. Assumptions 
of the linear regression and multicollinearity were checked.
resUlTs
clinical characteristics
Fourteen patients (mean age 56 years, range 46–70) and 14 con-
trols (mean age 54 years, range 39–70) were included in the study. 
Two controls, however, were excluded from the analysis. One 
healthy control prematurely stopped the scanning procedure. 
The other subject was excluded due to subcutaneous infusion of 
the tracer. After excluding these two controls from the analysis, 
the two groups under study were still age- and gender matched 
(Table 1).
The patients had a median dystonia duration of 9 years (range 
1–52) years. The total TWSTRS score was 36.4 (SD ± 15.9) and 
the CGI-S jerks/tremor score 1.9 (SD ± 0.8). All patients had a 
combination of rotation and laterocollis, with some patients also 
having antero- or retrocollis, lateral- or sagittal shift, or very mild 
tremor. Most of the measured NMS scores were statistically sig-
nificantly higher in the CD patients as compared with the controls, 
with values for depressive symptoms (BDI) of 12.6 (SD ± 6.6) vs. 
3.6 (SD ± 3.9) (p < 0.01), anxiety (BAI) 8.9 (SD ± 5.6) vs. 3.9 
(SD ± 3.6) (p = 0.01), and fatigue (FSS) 38.8 (SD ± 14.3) vs. 22.9 
(SD ± 6.6) (p < 0.01). Sleep disturbances (PSQI) were also more 
severe in CD patients, but the difference did not reach statistical 
significance: 8.3 (SD ± 3.8) vs. 5.3 (SD ± 4.3) (p = 0.16).
The prevalence of the LA/LA genotype was not significantly 
different in patients and controls (42 vs. 21%, p = 0.40).
Volumes of interest-Based analysis of 
[11c]DasB Binding
The distribution of [11C]DASB in control subjects revealed 
strong binding in the dorsal midbrain, thalamus, and striatum 
(Figure 1).
No statistically significant differences in the BPND of SERT 
between CD patients and controls were detected with the 
TaBle 2 | BPND in CD patients and controls in volumes of interest (VOIs).
cD (n = 14) controls (n = 12)
Frontal cortex 0.33 ± 0.07 0.36 ± 0.06
Anterior cingulate cortex 0.43 ± 0.08 0.47 ± 0.09
Thalamus 1.24 ± 0.24 1.31 ± 0.22
Caudate nucleus 0.90 ± 0.37 0.89 ± 0.33
Pallidum 1.39 ± 0.30 1.51 ± 0.27
Putamen 1.57 ± 0.29 1.73 ± 0.27
S. Nigra 1.96 ± 0.66 1.82 ± 0.21





 – dRNa 5.29 ± 1.32 4.79 ± 1.84
 – dRNs 6.78 ± 1.62 5.54 ± 3.42
mRN
 – mRNa 9.67 ± 5.08 6.78 ± 2.28
 – mRNs 10.02 ± 4.76 7.43 ± 1.72
The BPND of the different volumes of interest in CD patients and controls. No significant 
differences were detected. Data are shown as mean ± SD. CD, cervical dystonia; 
BPND, binding potential, non-displaceable; dRN, dorsal raphe nucleus, atlas based 
(dRNa) or subject based (dRNs); mRN, median raphe nucleus, atlas based (mRNa) or 
subject based (mRNs).
FigUre 1 | Binding potential non-displaceable (BPND).
TaBle 1 | Demographic and clinical characteristics.
cD (n = 14) controls (n = 12) Maximum value clinical relevant p-Value
Age 56 ± 9 years 53 ± 8 years ns
Female 12 (86%) 10 (83%) ns
Dystonia duration 12 ± 13 years
TWSTRS












CGI-S tremor/jerks 1.9 ± 0.8 7
BDI 12.6 ± 6.6 3.6 ± 3.9 63  ≥10 0.01
BAI 8.9 ± 5.6 3.9 ± 3.6 63  ≥10  <0.01
FSS 38.8 ± 14.3 22.9 ± 6.6 63  ≥36  <0.01
PSQI 8.3 ± 3.8 5.3 ± 4.3 21  ≥5 ns
LA/LA genotype 3 (21%) 5 (42%) ns
Injected dose [11C]DASB (MBq) 387 ± 33.5 371 ± 53 ns
Demographic and clinical characteristics of CD patients and controls, including the maximum values of the different motor and non-motor scales and clinically relevant values. Data 
shown as mean ± SD or number (%).
CD, cervical dystonia, Y, years; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; CGI-S, Clinical Global Impression Scale; BDI, Beck Depression Inventory; BAI, Beck 
Anxiety Inventory; FSS, Fatigue Severity Scale; PSQI, Pittsburgh Sleep Quality Index.
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VOI-based analysis (Table  2). Neither were significant asym-
metries detected between the left and right VOIs in any of the 
groups (data not shown).
A trend with substantial effect size was detected toward 
decreased binding in the putamen of CD patients (9.3% decrease, 
d = 0.57, p = 0.09). Although the [11C]-DASB BPND was higher 
in the in the raphe nuclei of patients as compared with controls, 
this difference was not statistically significant in the dRN (dRNs 
18.3% increase, d = 0.46, p = 0.21; dRNa 9.5% increase, d = 0.31, 
p =  0.22) nor in the mRN (mRNs 25.8% increase, d =  0.72, 
p = 0.16; mRNa 29.9% increase, d = 0.73, p = 0.45).
Voxel-Based analysis of [11c]DasB 
Binding
Similar to the VOI-based approach, the whole brain voxel-based 
analysis revealed no significant differences (p =  0.005, uncor-
rected) in the BPND between CD patients and controls.
correlations between clinical Variables 
and [11c]DasB Binding
In CD patients, motor symptom severity was significantly cor-
related with a higher BPND in the dRN (dRNs: rs = 0.65, p = 0.01; 
dRNa: rs = 0.60, p = 0.02). No other regions, particularly not the 
basal ganglia, showed such a correlation with motor symptom 
severity. Among the NMS scores, we found a significant correla-
tion between the BPND in the dRN and pain (dRNs: rs =  0.73, 
p < 0.01; dRNa: rs = 0.58, p = 0.03) and sleep disturbances (dRNs: 
rs = 0.73, p < 0.01, dRNa: rs = 0.71, p < 0.01) (Figure 2). Patients 
with the LA/LA genotype had a relatively low BPND in the dRNs, 
namely, 5.1, 5.2, and 5.4.
Subsequently, in the multiple regression analysis, we included 
motor symptom severity, scores on pain, and sleep disturbances 
to assess the effect on the BPND of the dRNs. As there was multicol-
linearity between pain and sleep disturbances scores (rs = 0.87, 
p <  0.01), this was performed in two separate steps. First, we 
included motor severity and pain in the model. This revealed an 
adjusted R2 of 0.47; none of the variables significantly influenced 
FigUre 2 |  Correlation between the BPND in the dRNs in CD patients and clinical variables. Univariate correlation analysis in CD patients between the BPND in the 
dRNs and the TWSTRS motor severity score, TWSTRS pain score, and PSQI score. The dashed line indicates the mean BPND in the dRNs of the control group. 
Patients with the LA/LA genotype are indicated as white circles. BPND, binding potential, non-displaceable; dNRs: dorsal raphe nucleus, subject based; CD, cervical 
dystonia; rs, Spearman’s rho; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; PSQI, Pittsburgh Sleep Quality Index.
TaBle 3 | Multiple regression analysis between the BPND of the dRNs and clinical variables.
Model region Predictors adjusted R2 B° β p-Value
1 dRNs  – TWSTRS severity
 – TWSTRS pain










2 dRNs  – TWSTRS severity
 – PSQI










Results of the multiple regression analysis to assess the effect of the TWSTRS severity score, the TWSTRS pain score, the PSQI score, and additional interaction effects on the 
BPND in the dRNs in CD patients. Due to multicollinearity between the TWSTRS pain score and PSQI score, we performed the analysis in two separate steps. For all variables, we 
calculated the B° (unstandardized coefficient with standard error in parenthesis) and β (standardized regression coefficient). BPND, binding potential, non-displaceable; dRNs, dorsal 
raphe nucleus, subject based; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; PSQI, Pittsburgh Sleep Quality Index.
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the model. Second, we included motor symptom severity and 
sleep disturbances in the model. This revealed an adjusted R2 of 
0.55, with motor symptom severity being the most important 
predictor of an increased BPND in the dRNs (β = 1.56, p = 0.02) 
(Table 3).
Furthermore, fatigue was negatively associated with the BPND 
in the mRN (mRNs: rs = −0.61, p = 0.045, mRNa: rs = −0.63, 
p = 0.049), while the domain sleep disorders was positively asso-
ciated with the BPND in the caudate nucleus (rs = 0.58, p = 0.03) 
and the hippocampus (rs = 0.56, p = 0.02).
DiscUssiOn
In this functional brain imaging study, we demonstrated, to the 
best of our knowledge for the first time, statistically significant 
positive correlations between [11C]DASB BPND in the dRN of 
CD patients and the severity of dystonic motor symptoms, 
pain scores, and sleep disturbances, but not with psychiatric 
comorbidity. Interestingly, the regression analysis showed that 
particularly the severity of the motor symptoms was the most 
important predictor of the model. Also, we found a trend toward 
a decrease of SERT binding in the putamen. Finally, scores of 
fatigue were negatively associated with the BPND in the mRN, 
while sleep disorder symptoms showed an association with BPND 
in the caudate nucleus and hippocampus.
The dRN and mRN are part of the eight raphe nuclei located 
within the brainstem. From these nuclei, serotonergic neurons 
project to several brain regions, including the basal ganglia, 
limbic region and cerebral cortex (20). SERT is highly prevalent 
both in the raphe nuclei and in the output areas, and forms an 
important presynaptic regulator of the serotonergic system. The 
highly presented SERT in regions involved in motor control (i.e., 
the basal ganglia) and in regions involved in NMS (i.e., the limbic 
region) and the functional interrelationship between these areas 
(21) suggest that alterations of SERT activity could contribute to 
the dystonia phenotype.
Increased SERT binding in the raphe nuclei related to 
motor and NMS in our cohort of CD patients might suggest an 
increased serotonergic state in CD, although causal relationships 
could not be extracted from this. The increased SERT binding 
could be explained by an upregulation due to an increased level 
of serotonin in the synaptic cleft. An increased serotonergic state 
related to dystonia is supported by many case reports of dystonia 
induced by selective serotonin reuptake inhibitors, but also by 
ondansetron, a potent 5-HT3 receptor antagonist [for review 
see Ref. (2)]. Further evidence of an increased serotonergic 
6Smit et al. Serotonergic Disturbances in CD
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activity came from animal studies and studies describing other 
hyperkinetic extrapyramidal disorders. In both cat and monkey, 
serotonin injections in the facial nucleus induced focal dystonia 
of the eyelids (22). Also, administering the precursor of seroto-
nin elicits a consistent hyperkinetic motor syndrome including 
lateral head waving (23). At the spinal cord level, serotonin 
increases spinal motor neuron excitability, facilitating the gen-
eration of action potentials. Dyskinesia is another condition of 
increased motor activity, occurring in Parkinson’s disease and 
it is associated with an increased ratio of SERT vs. dopamine 
transporter binding (7).
Opposite to the increased binding in the raphe nuclei, we 
found a trend toward decreased SERT binding in the putamen. 
One might argue that increased serotonergic activity in the raphe 
nuclei may increase 5-HT1A autoreceptor activation within the 
same area, which results in an inhibitory effect on discharge 
patterns to the output areas, including the putamen (21). 
Interestingly, in Parkinson’s disease such reduced serotonergic 
activity in the basal ganglia by stimulating inhibitory 5-HT1A 
receptors may ameliorate dyskinesia (7).
Not only motor severity but also pain and sleep disturbances 
showed a positive correlation with the BPND in the dRN. 
Moreover, sleep disturbance symptoms were also associated 
with SERT binding in the caudate nucleus and hippocampus. 
Serotonin involvement in pain is supported by previous studies. 
For example, spinal analgesic action is mediated by serotonin 
release, and selective serotonin reuptake inhibitors induce a 
central analgesic effect (24). In sleep disorders, altered discharge 
patterns of serotonergic neurons were suggested to be involved 
by influencing the different serotonergic postsynaptic receptors 
(25). Particularly, the REM sleep seems to be controlled by 
serotonergic activity. The REM sleep paralysis is mediated by 
inhibition of motoneurons, during which activity of serotonergic 
neurons is also suppressed. Moreover, inactivation of the dRN in 
animals caused a condition similar to REM sleep and simulta-
neously induced muscle paralysis (23). Altogether, the relation 
between SERT binding in the dRN and motor severity, pain, 
and sleep disturbances supports our hypothesis that serotonin 
forms a shared pathophysiological pathway of motor and NMS 
in dystonia.
For the interpretation of our results, it is important to keep 
in mind that the level of regionally measured [11C]DASB BPND 
reflects the Bmax/Kd, or in other words the number of SERTs, 
and the affinity of the radiotracer for the SERT, which may be 
influenced by the quantity of endogenous synaptic serotonin, 
competing at the binding sites. For example, an increase of 
endogenous serotonin may reduce [11C]DASB binding without 
a change in the actual number of binding sites. The latter has 
particularly been demonstrated in acute experimental condi-
tions of drugs employed to manipulate serotonin availability 
(26). However, in chronic conditions of low-serotonin con-
centrations, a downregulation of SERT is thought to occur to 
preserve synaptic 5-HT levels. Thus, lower binding in the basal 
ganglia output regions may be explained by several mechanisms, 
and the mechanism involved in our study is as yet unclear. 
Although the patients included in our study were characterized 
by a distinct profile of symptoms, the finding of a significant 
correlation between symptom severity and increased dRN [11C]
DASB binding provides a strong argument to regard this dRN 
binding as a fair indicator of increased presynaptic serotonergic 
activity.
This study has some limitations. Scans were performed on 
two different cameras. However, both cameras are in the same 
center, are almost similar, and use the same reconstruction 
protocol. We did not include age and gender as covariates. As 
participants were matched on age and gender, we do not believe 
this decision significantly influenced the results. Side-related 
correlations between SERT binding and clinical characteris-
tics (e.g., rotation, lateroflexion) could unfortunately not be 
answered based on 14 participating patients. Another limitation 
is that motor scores were obtained during the period with the 
least influence of botulinum toxin, while the scans were per-
formed in the period of the maximum botulinum toxin effect. 
Therefore, the different SERT binding between CD patients 
and controls might even be an underestimation, caused by the 
therapeutic effect of botulinum toxin. Another consideration 
is the effect of BoNT on SERT binding. While BoNT may enter 
the spinal cord, a neurochemical interaction with brainstem 
serotonin neurotransmission does not seem plausible. On the 
other hand, the BoNT effect of (temporary) dystonic relief has 
indeed been described to induce altered functional network 
organization. For example, functional imaging studies (27, 28) 
have shown that BoNT therapy was associated with an increase 
in BOLD response in particularly somatosensory-related brain 
regions. The methodology underlying such functional imag-
ing studies, including repeated within subject measurements 
to achieve statistical power, enables identification of subtle 
changes in responses. PET imaging with SERT implies investi-
gating the more basal cerebral alterations of a neurotransmitter 
system at a steady-state condition. For this reason, we do not 
assume that BoNT had an effect on tracer uptake in the PET 
method.
Another limitation concerns the relationship between NMS 
and SERT binding in CD patients, while we could not examine 
this possible relation in the control group as those symptoms 
were lacking. In the future, it would be interesting to examine 
a possible relation between those symptoms and SERT bind-
ing independently from the dystonia pathophysiology, which 
would enable to discriminate between pathophysiology-related 
relationships or independent processes. At least, SERT binding 
in the raphe nuclei is challenging, due to the small size com-
prising only a couple of voxels. Therefore, we measured SERT 
binding in the dRN and mRN in two separate ways, namely, 
based on the MNI coordinates and visually by selecting the 
most active voxels. Because both techniques showed the same 
results, we do think we reliably measured SERT binding in the 
raphe nuclei.
In conclusion, this study provides the first evidence of the 
involvement of the serotonergic system in both motor and NMS 
in CD, which motivates the design of future studies focusing 
on this neurotransmitter system, including imaging studies on 
serotonin receptors. Eventually, such an approach may pave the 
way to evaluate the effect of serotonergic drugs on the motor and 
NMS symptoms in CD.
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